

Summary of status of development and availability of influenza B (Yamagata and Victoria lineage) candidate vaccine viruses* and potency testing reagents

*Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance Network. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

4 May 2011

Candidate vaccine viruses B-Victoria lineage

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Brisbane/33/2008	Wild type virus			NIBSC, UK
B/Brisbane/60/2008	Wild type virus			WHO CCs NIBSC, UK NIID, Japan
	NIB-58	Classical	NIBSC, UK	NIBSC, UK
	NYMC BX-31 [#]		New York Medical College, (NYMC) USA	NYMC, USA NIBSC, UK
	NYMC BX-31B [#]			NYMC, USA
	NYMC BX-31-CL [#]			NYMC, USA CDC, USA
	NYMC BX-33 ^{##}			NYMC, USA CDC, USA
	NYMC BX-33B ^{##}			NYMC, USA NIID, Japan
	NYMC BX-35 ^{###}			NYMC, USA NIBSC, UK NIID, Japan
B/Bangladesh/5945/2009	NYMC BX-37 ^{##}			NYMC, USA CDC, USA

[#] B/Lee/40 backbone parent

^{##} B/Panama/45/90 backbone parent

^{###} B/Lee/40 and B/Panama/45/90 backbone parents

Candidate vaccine viruses - continued

B-Victoria lineage

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/HongKong/259/2010	Wild type virus			CDC, USA
	NYMC BX-43 [#]	Classical	NYMC, USA	NYMC, USA
	NYMC BX-43A [#]	Classical	NYMC, USA	NYMC, USA
	NYMC BX-43B [#]	Classical	NYMC, USA	NYMC, USA

[#] B/Lee/40 backbone parent

^{##} B/Panama/45/90 backbone parent

^{###} B/Lee/40 and B/Panama/45/90 backbone parents

B-Yamagata lineage

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
B/Hubei-Wujiagang/158/2009	Wild type virus			CDC, USA
	NYMC-BX-39 ^{###}	Classical	NYMC, USA	NYMC, USA
B/Wisconsin/1/2010	Wild type virus			CDC, USA
	NYMC-BX-41A [#]	Classical	NYMC, USA	NYMC, USA

[#] B/Lee/40 backbone parent

^{##} B/Panama/45/90 backbone parent

^{###} B/Lee/40 and B/Panama/45/90 backbone parents

Institutes contact details for candidate vaccine viruses' orders/information:

NIBSC: standards@nibsc.hpa.org.uk or enquiries@nibsc.hpa.org.uk
 NIID: sitamura@nih.go.jp
 NYMC: doris_bucher@nymc.edu
 CDC: fluorder@cdc.gov

Reference antigens (freeze-dried)

Starting materials			Ref Ag	Unitage	Available from
Parent virus	CVV	Egg or Cell	Lot #	(µgHA/mL)	
B/Brisbane/60/2008 (wild type)		Egg	08/352	27	NIBSC
			*2011/89B	74	TGA
			68	60	CBER/FDA
			2010BA	63	NIID
	NYMC BX-35		10/106	48	NIBSC

new lot*Sheep antisera**

Purified HA from		Order / Lot #	Available from
Parent virus	Egg or Cell		
B/Brisbane/60/2008 (wild type)	Egg	10/146	NIBSC
		*AS397-1	TGA
		B-Ab-0913	CBER/FDA
		2010B-1	NIID

***new lot number**

The above-listed potency testing reagents for B/Brisbane/60/2008-like vaccines have been developed with support from manufacturers, and calibrated by the Essential Regulatory Laboratories (ERLs) that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagents orders/information: :

NIBSC: standards@nibsc.hpa.org.uk

TGA: influenza.standards@tga.gov.au

NIID: sitamura@nih.go.jp

For general enquiries, please contact GISN@who.int

For other candidate vaccine viruses and potency testing reagents, please go to
<http://www.who.int/csr/disease/influenza/vaccinerecommendations2/en/index.html>